Jazz Pharmaceuticals Announces Acquisition of Actio Biosciences

What Happened
On September 15, 2026, Jazz Pharmaceuticals plc filed a Form 8‑K (Item 7.01) and issued a press release announcing the completion of its acquisition of Actio Biosciences, Inc. Following the closing, Actio became a wholly‑owned subsidiary of Jazz. The press release is attached to the 8‑K as Exhibit 99.1 (Item 9.01).

Key Details

• Filing date: September 15, 2026.
• Transaction status: Acquisition completed; Actio Biosciences, Inc. is now a wholly‑owned subsidiary of Jazz.
• Disclosure type: Regulation FD disclosure via press release (Exhibit 99.1).
• The Form 8‑K does not include purchase price, financial terms, or pro forma financial statements.

Why It Matters
The 8‑K notifies investors that Jazz has closed an acquisition that could affect its product pipeline, operations, or future results. Because this disclosure is limited to the press release, investors should watch for follow‑up SEC filings (e.g., required financial statements, pro forma information, or additional management commentary) for details on the transaction’s financial impact and integration plans. Review the attached press release and subsequent filings for full terms and expected effects on Jazz’s financials.